Nido Biosciences is a clinical-stage company developing precision small-molecule medicines that target fundamental biology to restore healthy cell function in neurological diseases. Its lead clinical candidate, NIDO-361, is being developed to treat Spinal and Bulbar Muscular Atrophy (SBMA). The company also pursues programs against a novel target intended to prevent cell death, reduce protein aggregates, and slow neuroinflammation, with potential application across neurodegenerative and peripheral inflammatory diseases. Nido leverages a functional genomics discovery platform based on human cell lines to identify therapeutic targets for ALS, frontotemporal disorders (FTD), and other neuromuscular and neurodegenerative diseases. The company emerged from stealth and has built a leadership team of experienced drug developers and industry advisors. Financially, Nido announced a combined $109 million raised across Seed, Series A and Series B financings.

Total raised

$109M

Funding rounds

3

Latest round

Seed

Latest activity

May 2023